Apollomics (APLM) Intangibles (2020 - 2023)

Apollomics (APLM) posted quarterly Intangibles of $14.8 million for Q2 2023, up 460.43% quarter-over-quarter from -$4.1 million in Q4 2022.

Apollomics (APLM) Intangibles (2020 - 2023) Analysis & Trends

Apollomics (APLM) has reported Intangibles for 4 consecutive years, with $14.8 million the latest figure, recorded in Q2 2023.

In Q2 2023, Intangibles changed N/A year-over-year to $14.8 million; the TTM figure through Jun 2023 stood at $14.8 million (changed N/A YoY), while the FY2022 annual figure was -$4.1 million, changed 0.49% from the prior year.
Intangibles improved to $14.8 million in Q2 2023 per APLM's latest filing, from -$4.1 million in the prior quarter.
Across five years, Intangibles topped out at $14.8 million in Q2 2023 and bottomed at -$4.1 million in Q4 2022.
Historically, Intangibles has averaged $4.5 million across 4 years, with a median of $3.6 million in 2020.
Annual changes were most pronounced in 2021 — Intangibles plunged 135.84% — and 2022, when it slipped 0.49%.
Apollomics' Intangibles stood at $11.4 million in 2020, then slumped by 135.84% to -$4.1 million in 2021, then slipped by 0.49% to -$4.1 million in 2022, then soared by 460.43% to $14.8 million in 2023.
Business Quant data shows APLM's Intangibles at $14.8 million in Q2 2023, -$4.1 million in Q4 2022, and -$4.1 million in Q4 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Intangibles (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	412.80 Mn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	1.31 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	266.00 Mn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	60.96 Mn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	-
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	93.49 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-
10	Apollomics	34.08 Mn	30.81 Mn	-	-

Download Data